MPTH-21MOLECULAR CHARACTERISTICS AND CLINICAL OUTCOME OF GLIOMA PATIENTS.: EXPERIENCE OF KANSAI NETWORK FOR MOLECULAR DIAGNOSIS OF CENTRAL NERVOUS SYSTEM TUMORS

BACKGROUND: Novel molecular aberrations are found and their prognostic or predictive values are reported. We have established a network for genetical analysis for central nervous system tumors in Kansai area, Japan. METHODS: We retrospectively reviewed clinical records of histologically proven 144 glioma patients (grade4: 88, grade3; 30, grade2: 30) treated by institutes accompanied with Kansai network for molecular diagnosis of central nervous system tumors between 2004-2014. Surgical specimen which were obtained at an initial surgery were used for molecular characterization. We investigated methylation status of MGMT promoter by methylation specific realtime PCR. Mutation of IDH1(R132H), IDH2 and TERT promoter were analyzed by Sanger method. Survival proportion was calculated by Kaplan Meyer method. RESULTS: Median time of overall survival (OS) of grade 4 and grade3 gliomas were 77 and 190 weeks, respectively, OS of grade4 and grade3 patients with methylated MGMT promoter was significantly longer than those without methylation status (151 versus 75.6 weeks, p = 0.0027). IDH1 mutation was found in 23/30, 16/30 and 5/88 cases of grade2, grade3 and grade, respectively. Mutation of TERT promoter was detected in 16/30, 13/30 and 40/87 cases of grade2, grade3 and grade, respectively. CONCLUSION: These data bring us important information to decide how to treat glioma patients. And analysis of glioma patients include who do not match for clinical trial may reveal more practical clinical course and aspects.